Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2020British Journal of HaematologyOpen Access

Upsetting the apple CAR‐T (chimeric antigen receptor T‐cell therapy) ‐ sustainability mandates USA innovation

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJeremy PantinSarah CannonMBMinoo BattiwallaCentennial Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pantin et al. (2020) studied this question.

synapsesocial.com/papers/6a1c613fea84844e355fce00https://doi.org/10.1111/bjh.16685
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England2019 · 34 citations
  2. 2Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma2019 · 226 citations
  3. 3Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia2018 · 131 citations
  4. 4Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods2019 · 89 citations
  5. 5Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions2018 · 130 citations